{"entity":{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","aka":["SASCIA"],"tldr":"A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting.","summary":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer. ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is planned at 1332 participants. Primary completion is estimated at 2027-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Capecitabine, Carboplatin, Cisplatin, Sacituzumab govitecan. Registered primary measures: Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice..","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04595565","url":"https://clinicaltrials.gov/study/NCT04595565"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy","platinum"],"targets":["trop2"],"drugs":["capecitabine","carboplatin","cisplatin","sacituzumab-govitecan"],"companies":["gbg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-04-22: active not recruiting. Enrollment is planned at 1332 participants. Primary completion is estimated at 2027-03-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04595565","phase":"3","setting":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","sponsor":"GBG Forschungs GmbH","participation":[{"nct":"NCT04595565","source":"https://clinicaltrials.gov/study/NCT04595565","fetchedAt":"2026-10-07T16:53:23.186Z","studySha256":"500143630b99382d7f43bfd70bbc5ed376affab9671196331698cfc5aecce77a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-22","leadSponsor":"GBG Forschungs GmbH","collaboratorCount":6,"minimumAge":"18 Years","maximumAge":"99 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1332,"enrolmentType":"ESTIMATED","siteCount":163,"recruitingSiteCount":0,"countries":["Austria","Belgium","France","Germany","Ireland","Spain","Switzerland"]}],"started":"2020-10-28","startedType":"actual","enrolled":1332,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04595565/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}